Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.

Voros S, Joshi PH, Vazquez G, Roth G, Murrieta L, Rinehart S, Qian Z, Miller J.

J Cardiovasc Comput Tomogr. 2010 May-Jun;4(3):164-72. doi: 10.1016/j.jcct.2010.03.005. Epub 2010 Mar 17.

PMID:
20413364
2.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
3.
4.

Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.

Sharma R, Mahajan M, Singh B, Bal BS, Kant R.

J Indian Med Assoc. 2006 Sep;104(9):492-4, 496, 498.

PMID:
17388006
5.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
6.

Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.

Choi SH, Chae A, Miller E, Messig M, Ntanios F, DeMaria AN, Nissen SE, Witztum JL, Tsimikas S.

J Am Coll Cardiol. 2008 Jul 1;52(1):24-32. doi: 10.1016/j.jacc.2008.02.066.

7.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
9.

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators.

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079.

10.

Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.

Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.

Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000.

PMID:
19995098
12.

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.

Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, Koizumi T, Nameki M, Fitzgerald PJ, Komuro I.

Am Heart J. 2005 Aug;150(2):287.

PMID:
16086932
13.
14.

Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the New Age II Pilot Study.

Burgstahler C, Reimann A, Beck T, Kuettner A, Baumann D, Heuschmid M, Brodoefel H, Claussen CD, Kopp AF, Schroeder S.

Invest Radiol. 2007 Mar;42(3):189-95.

PMID:
17287649
15.

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS.

J Cardiovasc Risk. 1999 Apr;6(2):113-6.

PMID:
10353071
16.

A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.

Dogra G, Irish A, Chan D, Watts G.

Am J Kidney Dis. 2007 Jun;49(6):776-85.

PMID:
17533020
17.

Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial.

Hong SJ, Chang HJ, Park S, Kang DR, Shin S, Cho IJ, Shim CY, Hong GR, Ha JW, Chung N.

Clin Cardiol. 2013 Aug;36(8):480-5. doi: 10.1002/clc.22152. Epub 2013 Jun 10.

18.
19.

Effects of lipid-lowering therapy on coronary artery remodeling.

Schartl M, Bocksch W, Fateh-Moghadam S.

Coron Artery Dis. 2004 Feb;15(1):45-51.

PMID:
15201620
20.

Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.

Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD.

J Am Coll Cardiol. 2005 Jul 5;46(1):166-72. Erratum in: J Am Coll Cardiol. 2011 Oct 18;58(17):1832.

Items per page

Supplemental Content

Write to the Help Desk